Open AccessIn vitro activity of LY 264826 compared with that of vancomycin against 100 clinical isolates each of methicillin-resistant Staphylococcus aureus and Clostridium difficile
Author(s) -
Elizabeth L. Fasola,
Julia Moody,
Dale N. Gerding,
Lance R. Peterson
Publication year - 1990
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.34.10.2007
Subject(s) - vancomycin , microbiology and biotechnology , clostridium difficile , staphylococcus aureus , glycopeptide , methicillin resistant staphylococcus aureus , antibiotics , in vitro , micrococcaceae , clostridium , biology , antibacterial agent , bacteria , biochemistry , genetics
The in vitro activity of LY 264826, a new glycopeptide antibiotic, was compared with that of vancomycin against 100 strains each of methicillin-resistant Staphylococcus aureus and Clostridium difficile. LY 264826 was more active, by weight, than vancomycin against the isolates tested. The human serum protein binding of LY 264826 was 15.3% (range, 9.8 to 21.8%).